In the article written by Jaclyn Cosgrove and published in the April 7, 2012, edition of the Oklahoma, "Cindy Hamilton, at the Oklahoma State Board of Pharmacy said that Lowlyn ha[d] not come come before the board and [wa]s not scheduled to be disciplined on Thursday (April 11, 2012) at the board's April meeting." This begs the question WHY NOT? Why would the Oklahoma State Board of Pharmacy not take disciplinary action against Lowlyn after the FDA issued 483 issued on March 8, 2013, finding deficiencies in Lowlyn's sterile process?
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Showing posts with label A Followup to the Oklahoman Story Regarding Lowlyn Pharmacy in Blanchard. Show all posts
Showing posts with label A Followup to the Oklahoman Story Regarding Lowlyn Pharmacy in Blanchard. Show all posts
Subscribe to:
Posts (Atom)